Population pharmacokinetics of sildenafil in extremely premature infants
Aims To characterize the population pharmacokinetics (PK) of sildenafil and its active metabolite, N‐desmethyl sildenafil (DMS), in premature infants. Methods We performed a multicentre, open‐label trial to characterize the PK of sildenafil in infants ≤28 weeks gestation and
Gespeichert in:
Veröffentlicht in: | British journal of clinical pharmacology 2019-12, Vol.85 (12), p.2824-2837 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Aims
To characterize the population pharmacokinetics (PK) of sildenafil and its active metabolite, N‐desmethyl sildenafil (DMS), in premature infants.
Methods
We performed a multicentre, open‐label trial to characterize the PK of sildenafil in infants ≤28 weeks gestation and |
---|---|
ISSN: | 0306-5251 1365-2125 1365-2125 |
DOI: | 10.1111/bcp.14111 |